logo

For the Inventor, By the Inventor

Amsterdam, Netherlands

Aimm Therapeutics B.v.


USPTO Granted Patents = 22

% Expired Patents = 31.8


Forward Citations = 43

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Tim Beaumont (16 out of 30 patents)

silverMedal Hergen Spits (13 out of 26 patents)

bronzeMedal Mark Jeroen Kwakkenbos (12 out of 18 patents)

4.  Eric J Brown (6 out of 12 patents)

5.  Sanjeev Mariathasan (6 out of 16 patents)

6.  John Hiroshi Morisaki (6 out of 11 patents)

7.  Wouter L W Hazenbos (6 out of 7 patents)

8.  Kimberly Kajihara (6 out of 7 patents)

9.  Yi Xia (6 out of 7 patents)

10.  Adrianus Quirinus Bakker (6 out of 16 patents)

11.  Koen Wagner (4 out of 5 patents)

12.  Remko Schotte (2 out of 3 patents)

13.  Etsuko Yasuda (2 out of 9 patents)

14.  Ferenc A Scheeren (2 out of 5 patents)

15.  Sean A Diehl (2 out of 3 patents)


22 patents:

1. 11136407 - Therapeutic anti-CD9 antibody (2021-10-05),
2. 10774308 - Means and methods for influencing the stability of cells (2020-09-15),
3. 10690658 - Means and methods for determining T cell recognition (2020-06-23),
4. 10611829 - Means and methods for producing stable antibodies (2020-04-07),
5. 10556963 - Means and methods for counteracting myeloproliferative or lymphoproliferative disorders (2020-02-11),
6. 10344076 - Means and methods for producing high affinity antibodies (2019-07-09),
7. 10077427 - Means and methods for influencing the stability of cells (2018-09-18),
8. 10017562 - RSV G protein specific antibodies (2018-07-10),
9. 9969795 - Means and methods for producing high affinity antibodies (2018-05-15),
10. 9927428 - Gram-positive bacteria specific binding compounds (2018-03-27),
11. 9822339 - Means and methods for influencing the stability of antibody producing cells (2017-11-21),
12. 9718876 - RSV G protein specific antibodies (2017-08-01),
13. 9718874 - Influenza A virus specific antibodies (2017-08-01),
14. 9688745 - Gram-positive bacteria specific binding compounds (2017-06-27),
15. 9458228 - Gram-positive bacteria specific binding compounds (2016-10-04),
Company Overview
Aimm Therapeutics B.V. is a biotechnology company based in Amsterdam, specializing in the development of innovative therapeutic solutions. The organization focuses on harnessing advanced technologies to create targeted treatments, particularly in the fields of oncology and immunology. Aimm Therapeutics is dedicated to addressing unmet medical needs through its research initiatives, leveraging expertise in drug development and precision medicine to enhance patient outcomes and improve healthcare solutions globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Aimm Therapeutics B.v. USPTO Patent Assignee Logo
22 Patents

#35 in Amsterdam

#325 in Netherlands

#28,807 in the World

Amsterdam, NL
Amsterdam, Netherlands

Aimm Therapeutics B.v.

Forward Citations = 43

28 inventors:

goldMedal Tim Beaumont (16 out of 30 patents)

silverMedal Hergen Spits (13 out of 26 patents)

bronzeMedal Mark Jeroen Kwakkenbos (12 out of 18 patents)

4.  Eric J Brown (6 out of 12 patents)

5.  Sanjeev Mariathasan (6 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aimm Therapeutics B.v.. Retrieved from https://idiyas.com/company/aimm-therapeutics-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…